Payment overview · 2025
General Payments
$308.06
16 reported records · 14 companies
Healthcare provider profile · identity verified
Mark Gregory Yohe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FARGO, ND · NPI 1346403995
Verified facts
What the public records show
CMS Open Payments records show Mark Gregory Yohe, M.D. received $308.06 in general payments during 2025 across 16 reported records.
Boston Scientific Corporation accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $60.28 | 19.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.29 | 9.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.38 | 8.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.15 | 8.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.38 | 7.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $21.29 | 6.9% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.02 | 6.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.54 | 5.4% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $15.86 | 5.2% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.71 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.31 | 5.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $14.37 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.96 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.52 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.06 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $38.83 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
260 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 506 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 132 |
| Lisinopril | Lisinopril | 437 | 113 |
| Losartan Potassium | Losartan Potassium | 301 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 280 | 84 |
| Eliquis | Apixaban | 260 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 61 |
| Metformin Hcl | Metformin Hcl | 197 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 58 |
| Simvastatin | Simvastatin | 179 | 48 |
| Ozempic | Semaglutide | 167 | 24 |
| Omeprazole | Omeprazole | 156 | 44 |
| Gabapentin | Gabapentin | 137 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 36 |
| Lorazepam | Lorazepam | 124 | 21 |
| Trazodone Hcl | Trazodone Hcl | 105 | 28 |
| Allopurinol | Allopurinol | 100 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 16 |
| Finasteride | Finasteride | 97 | 22 |
| Carvedilol | Carvedilol | 92 | 24 |
| Furosemide | Furosemide | 85 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Sertraline Hcl | Sertraline Hcl | 79 | 24 |
| Tramadol Hcl | Tramadol Hcl | 79 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 22 |
| Mirtazapine | Mirtazapine | 61 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 59 | 14 |
| Bupropion Xl | Bupropion Hcl | 58 | 14 |
| Farxiga | Dapagliflozin Propanediol | 56 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Prednisone | Prednisone | 54 | 26 |
| Alprazolam | Alprazolam | 53 | 16 |
| Atenolol | Atenolol | 53 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 24 |
| Baclofen | Baclofen | 46 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Valsartan | Valsartan | 44 | 13 |
| Metformin Hcl Er | Metformin Hcl | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Potassium Chloride | Potassium Chloride | 41 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 26 | 25 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.06 · 16 records | Boston Scientific Corporation | Ambulatory Monitoring & Diagnostics Undivided, General - Pain Management, HYMOVIS, ImmunoCAP, Intracept, Jornay PM, NUCALA, NURTEC ODT, OPSUMIT, QULIPTA, REZDIFFRA, STRENSIQ, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, VOQUEZNA, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error